HUP0102159A2 - Készítmény savtúltengés kezelésére - Google Patents

Készítmény savtúltengés kezelésére

Info

Publication number
HUP0102159A2
HUP0102159A2 HU0102159A HUP0102159A HUP0102159A2 HU P0102159 A2 HUP0102159 A2 HU P0102159A2 HU 0102159 A HU0102159 A HU 0102159A HU P0102159 A HUP0102159 A HU P0102159A HU P0102159 A2 HUP0102159 A2 HU P0102159A2
Authority
HU
Hungary
Prior art keywords
treatment
pharmaceutical composition
rumen acidosis
production
hyperacidity
Prior art date
Application number
HU0102159A
Other languages
English (en)
Inventor
Bernard Joseph Banks
Mark Andrew Haxell
Graham Lunn
Michael Stephen Pacey
Lee Richard Roberts
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0012760A external-priority patent/GB0012760D0/en
Priority claimed from GB0012793A external-priority patent/GB0012793D0/en
Priority claimed from GB0017495A external-priority patent/GB0017495D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HU0102159D0 publication Critical patent/HU0102159D0/hu
Publication of HUP0102159A2 publication Critical patent/HUP0102159A2/hu
Publication of HUP0102159A3 publication Critical patent/HUP0102159A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Sustainable Development (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Saccharide Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány bakteriális eredetű a-amilázt és/vagy a-glükozidázthatásosan gátló anyag alkalmazása savtúltengés kezelésére szolgálókészítmény előállítására. A találmány tárgyköréhez tartozik továbbáeljárás a fenti készítmény előállítására, eljárás savtúltengéskezelésére, valamint kérődzők tejtermelésének javítására. Ó
HU0102159A 2000-05-24 2001-05-23 Pharmaceutical composition for the treatment of rumen acidosis HUP0102159A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0012760A GB0012760D0 (en) 2000-05-24 2000-05-24 Treatment
GB0012793A GB0012793D0 (en) 2000-05-24 2000-05-24 Treatment
GB0017495A GB0017495D0 (en) 2000-07-17 2000-07-17 Treatment

Publications (3)

Publication Number Publication Date
HU0102159D0 HU0102159D0 (en) 2001-08-28
HUP0102159A2 true HUP0102159A2 (hu) 2002-01-28
HUP0102159A3 HUP0102159A3 (en) 2004-01-28

Family

ID=27255738

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102159A HUP0102159A3 (en) 2000-05-24 2001-05-23 Pharmaceutical composition for the treatment of rumen acidosis

Country Status (17)

Country Link
US (1) US20050233983A1 (hu)
EP (2) EP1745790A3 (hu)
JP (2) JP3798261B2 (hu)
KR (1) KR100643946B1 (hu)
AT (1) ATE343391T1 (hu)
AU (1) AU785303B2 (hu)
CA (1) CA2348245C (hu)
CY (1) CY1105796T1 (hu)
DE (1) DE60124030T2 (hu)
DK (1) DK1157696T3 (hu)
ES (1) ES2272418T3 (hu)
HU (1) HUP0102159A3 (hu)
IL (2) IL143225A (hu)
MY (1) MY136145A (hu)
NZ (1) NZ511877A (hu)
PT (1) PT1157696E (hu)
TW (1) TWI298021B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745790A3 (en) * 2000-05-24 2007-03-21 Pfizer Limited Treatment of rumen acidosis with alpha-amylase inhibitors
US7906128B2 (en) * 2002-10-21 2011-03-15 Wyeth Llc Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
CN1296050C (zh) * 2003-12-10 2007-01-24 浙江海正药业股份有限公司 阿卡波糖肠溶片及制备方法
CN101235061B (zh) * 2007-09-11 2011-03-30 南开大学 一类新的α-淀粉酶抑制剂阿卡他定系列化合物及其应用
US8791245B2 (en) * 2008-10-03 2014-07-29 Glycan Bioscience LLC Anionic conjugates of glycosylated bacterial metabolite
DE102009015558B4 (de) * 2009-03-30 2017-04-27 Ulf-Michael Stumpe Bollus zum Eingeben in die Vormägen von Wiederkäuern zur Verbesserung der Vormagenaktivität und Vormagengesundheit
US20130164275A1 (en) * 2009-10-26 2013-06-27 Pharmachem Laboratories, Inc. Method for treating acidosis in ruminants
CN102212089A (zh) * 2011-04-12 2011-10-12 天津医科大学 一类新的α-淀粉酶抑制剂阿卡他定家族新化合物及其应用
EP3375453A1 (de) * 2017-03-13 2018-09-19 Basf Se Verwendung einer pansengeschützen alpha-amylase
WO2020118345A1 (en) * 2018-12-14 2020-06-18 ProAgni Pty Ltd Animal feed composition
CN110899293A (zh) * 2019-10-15 2020-03-24 上海交通大学 一种对阿卡波糖废渣减量化处理的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4175123A (en) * 1976-12-23 1979-11-20 Bayer Aktiengesellschaft Amino-sugar derivatives, process for their preparation and pharmaceutical composition thereof
DE2658562A1 (de) * 1976-12-23 1978-10-12 Bayer Ag Aminozuckerderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
EP0173950A3 (de) * 1984-09-04 1987-10-28 Hoechst Aktiengesellschaft Neuer alpha-Glukosidase Inhibitor, Verfahren zur seiner Herstellung, seine Verwendung und pharmazeutische Präparate
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US4885361A (en) * 1987-07-31 1989-12-05 Hoffmann-La Roche Inc. Sulfated oligosaccharides
US5021427A (en) * 1988-12-23 1991-06-04 The Board Of Regents, The University Of Texas System Novel pyrrolizidine alkaloid
JP2001523704A (ja) * 1997-11-25 2001-11-27 バイエル・アクチエンゲゼルシヤフト α−グルコシダーゼ阻害剤を含んで成る持続放出性製剤
US7022684B2 (en) * 2000-05-24 2006-04-04 Pfizer Inc. Treatment of rumen acidosis with α-amylase inhibitors
EP1745790A3 (en) * 2000-05-24 2007-03-21 Pfizer Limited Treatment of rumen acidosis with alpha-amylase inhibitors

Also Published As

Publication number Publication date
DE60124030D1 (de) 2006-12-07
EP1745790A3 (en) 2007-03-21
JP2002047209A (ja) 2002-02-12
HU0102159D0 (en) 2001-08-28
EP1157696A2 (en) 2001-11-28
ATE343391T1 (de) 2006-11-15
CY1105796T1 (el) 2011-02-02
DK1157696T3 (da) 2007-02-12
JP2005336192A (ja) 2005-12-08
EP1745790A2 (en) 2007-01-24
EP1157696A3 (en) 2002-02-13
KR20010107661A (ko) 2001-12-07
CA2348245A1 (en) 2001-11-24
EP1157696B1 (en) 2006-10-25
IL186223A0 (en) 2008-01-20
NZ511877A (en) 2002-11-26
ES2272418T3 (es) 2007-05-01
PT1157696E (pt) 2007-01-31
JP3798261B2 (ja) 2006-07-19
AU785303B2 (en) 2007-01-04
KR100643946B1 (ko) 2006-11-10
IL143225A (en) 2008-03-20
MY136145A (en) 2008-08-29
US20050233983A1 (en) 2005-10-20
DE60124030T2 (de) 2007-04-12
CA2348245C (en) 2007-12-11
IL143225A0 (en) 2002-04-21
TWI298021B (en) 2008-06-21
HUP0102159A3 (en) 2004-01-28
AU4619201A (en) 2001-11-29

Similar Documents

Publication Publication Date Title
HUP0303728A2 (hu) Tápanyagkészítmény
ATE312635T1 (de) Ventilanordnung
HUP0203056A1 (hu) Vakcinakészítmény
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
TW200640486A (en) Composition
NZ331705A (en) Immediate release ph-independent solid dosage form of cisapride
MY162068A (en) Formulation of human antibodies for treating tnf-(alpha) associated disorders
HUP0102159A2 (hu) Készítmény savtúltengés kezelésére
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
HUP0400589A2 (hu) Kolosztrumalapú készítmény
HUP0301349A2 (hu) IL-11-tartalmú készítmények
DE59706808D1 (de) Verwendung von 7-(2-oxa-5,8-diazabicyclo 4.3.0]non-8-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur herstellung eines arzneimittels zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
BG108516A (en) Pharmaceutical formulation
DE60122672D1 (de) Zusammensetzung zur intestinalen verabreichung
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
HUP0300732A2 (hu) Chlamydiás fertżzések kezelésében és megelżzésében hatékony növényi-eredetż és szintetikus fenolos vegyületek és növényi extraktumok
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
EA200500031A1 (ru) Быстрораспадающаяся таблетка
MXPA02012857A (es) Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado.
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
AP2001002369A0 (en) Pharmaceutical complex.
HUP0003845A2 (hu) Antimikrobiális 8a-azalidok alkalmazása
PL1853308T3 (pl) Podawany drogą pokarmową preparat farmaceutyczny dla ryb, jego sposób wytwarzania oraz jego zastosowanie

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees